
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Март 17, 2025
A new generation of mucosal vaccine against the ever-evolving SARS-CoV-2 is great value to fight COVID-19. In previous studies, our groups developed a viral vector based on an avirulent Newcastle disease virus (NDV) expressing prefusion-stabilized spike protein (NDV-HXP-S). Here we characterized in vivo biodistribution and immunogenicity live NDV-HXP-S animal models. NDV showed restricted replication mice hamsters. Despite limited replication, intranasal provided protection challenge direct-contact transmission Importantly, trivalent (Wuhan, Beta, Delta) induced more cross-reactive antibody responses phylogenetically distant Omicron variant than ancestral vaccine. Furthermore, boosted systemic immunity pre-immunized with mRNA Overall, multivalent shows promise as safe, next-generation conferring broad future variants.
Язык: Английский